COVID-19/SARS-COV-2 / RESEARCH PAPER
Genomic variations in SARS-CoV-2 strains at the target
sequences of nucleic acid amplification tests
More details
Hide details
1
National Medical Center for Major Public Health Events, Tongji Hospital, Tongji
Medical College, Huazhong University of Science and Technology, Wuhan, China
2
Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong
University of Science and Technology, Wuhan, China
Submission date: 2020-11-07
Final revision date: 2021-01-22
Acceptance date: 2021-02-07
Online publication date: 2021-03-21
Corresponding author
Qinglei Gao
National Medical Center for Major Public Health Events, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Nucleic acid amplification is the main method used to detect
infections of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
However, the false-negative rate of nucleic acid tests cannot be ignored.
Material and methods:
Herein, we demonstrated genomic variations at the
target sequences for the tests and the geographical distribution of the variations across countries by analyzing the whole-genome sequencing data of
SARS-CoV-2 strains from the 2019 Novel Coronavirus Resource (2019nCoVR)
database.
Results:
Among the 21 pairs of primer sequences in regions ORF1ab, S, E,
and N, the total length of primer and probe target sequences was 938 bp,
with 131 (13.97%) variant loci in 2415 (38.96%) isolates. Primer targets in
the N region contained the most variations that were distributed among the
most isolates, and the E region contained the fewest. Single nucleotide polymorphisms were the most frequent variation, with C to T transitions being
detected in the most variant loci. G to A transitions and G to C transversions
were the most common and had the highest isolate density. Genomic variations at the three mutation sites N: 28881, N: 28882, and N: 28883 were
the most commonly detected, including in 608 SARS-CoV-2 strains from
33 countries, especially in the United Kingdom, Portugal, and Belgium.
Conclusions:
Our work comprehensively analyzed genomic variations at the
target sequences of the nucleic acid amplification tests, offering evidence to
optimize primer and probe target sequence selection, thereby improving the
performance of the SARS-CoV-2 diagnostic test.